Cat Allergy - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cat Allergy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cat Allergy - Pipeline Review, H1 2016', provides an overview of the Cat Allergy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cat Allergy
- The report reviews pipeline therapeutics for Cat Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cat Allergy therapeutics and enlists all their major and minor projects
- The report assesses Cat Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cat Allergy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cat Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cat Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Cat Allergy - Overview 7
Cat Allergy - Therapeutics under Development by Companies 8
Cat Allergy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Cat Allergy - Products under Development by Companies 12
Cat Allergy - Companies Involved in Therapeutics Development 13
ALK-Abello A/S 13
Amgen Inc. 14
Biomay AG 15
Circassia Pharmaceuticals Plc 16
Cat Allergy - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Allergen for Cat Allergy - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Allergen for Cat Allergy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BM-36 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Epsi-Gam - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tezepelumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Vaccine for Cat Allergy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Vaccine for Cat Allergy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cat Allergy - Recent Pipeline Updates 35
Cat Allergy - Dormant Projects 38
Cat Allergy - Discontinued Products 39
Cat Allergy - Product Development Milestones 40
Featured News & Press Releases 40
Jan 08, 2015: Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study 40
Feb 25, 2013: Circassia's ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy 40
Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 41
Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology 42
Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 42
Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 43
Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine 43
Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 44
Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for Cat Allergy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Cat Allergy - Pipeline by ALK-Abello A/S, H1 2016 13
Cat Allergy - Pipeline by Amgen Inc., H1 2016 14
Cat Allergy - Pipeline by Biomay AG, H1 2016 15
Cat Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Cat Allergy Therapeutics - Recent Pipeline Updates, H1 2016 35
Cat Allergy - Dormant Projects, H1 2016 38
Cat Allergy - Discontinued Products, H1 2016 39